FrancophonIA/ELRC3.0 huggingface dataset:
English: There are no data regarding the use of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics during breast-feeding.
Latvian: Nav datu par Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics lietošanu zīdīšanas periodā.
English: MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
Latvian: BIOLOĢISKI AKTĪVĀS VIELAS RAŢOTĀJS UN RAŢOŠANAS LICENCES ĪPAŠNIEKS, KURŠ ATBILD PAR SĒRIJAS IZLAIDI
English: Two doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were administered three weeks apart and a third dose 12 months following the first dose.
Latvian: Novartis Vaccines and Diagnostics devas tika ievadītas ar triju nedēļu intervālu un trešā dea 12 mēnešus pēc pirmās devas.
English: Seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibodies to H5N1 A/turkey/Turkey/05 after the 2
Latvian: Seroprotekcijas līmenis*, serokonversijas līmenis* un serokonversijas faktors** anti-HA antivielām pret H5N1 A/turkey/Turkey/05 pēc 2. devas piaugušajiem vecumā no 18 līdz 60 gadiem, mērot ar SRH un HI analīzēm, bija šāds.
English: There are no data on co-administration of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics with other vaccines.
Latvian: Nav datu par Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics ievadīšanu vienlaikus ar citām vakcīnām.
English: * propagated in eggs ** expressed in microgram haemagglutinin.
Latvian: 0,5 ml devā * pavairots olās ** izteikts mikrogramos hemaglutinīna.
English: In the event of an officially declared influenza pandemic due to A/H5N1 virus, persons previously vaccinated with one or two doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics that contained HA antigen derived from a different clade of the same influenza subtype as the influenza pandemic strain may receive a single dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics instead of two doses that are required in previously unvaccinated individuals (see section 5.1).
Latvian: Novartis Vaccines and Diagnostics devām, kurās bijis HA antigēns, kurš atvasināts no citas tā paša gripas vīrusa apakštipa grupas, kuram pieder pandēmijas gripas celms, var saņemt vienu Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
English: Intramuscular use
Latvian: DERĪGUMA TERMIĽŠ
English: • in the presence of immune deficiencies Prepandemic Influenza vaccine (H5N1) (surface antigen,
Latvian: • imūndeficīta gadījumā Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
English: Systemic
Latvian: Raţotājs
English: Study V87P3 21 days after 2
Latvian: V87P3 pētījums 21 dienu pēc 2. devas N=30
English: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspension for injection in pre-filled syringe Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Latvian: Novartis Vaccines and Diagnostics Kā lieto Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
English: All (100%) animals receiving 2 doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were protected, and 94% of animals receiving a single dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were protected.
Latvian: Visi (100%) dzīvnieki, kas saņēma 2 devas Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
English: Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a vaccine for use in adults (from 18 to 60 years old).
Latvian: Novartis Vaccines and Diagnostics ir vakcīna, kas lietojama pieaugušajiem (no 18 līdz 60 gadus veciem) un gados vecākām personām (vairāk kā 60 gadus vecām).
English: You should not receive Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics:
Latvian: Nelietojiet Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics šādos gadījumos:
English: METHOD AND ROUTE OF ADMINISTRATION To be administered intramuscularly into the deltoid muscle.
Latvian: Ievadīšanai intramuskulāri deltveida muskulī.
English: Important information about some of the ingredients of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics
Latvian: Svarīga informācija par kādu no Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
English: The following additional adverse events were reported from post-marketing surveillance with Focetria H1N1v (licensed for use from 6 months of age and with a composition that is similar to Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics):
Latvian: No Focetria H1N1v (atļauta lietošanai no 6 mēnešu vecuma un ar sastāvu, kas līdzīgs Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
English: It is available as tablets (160 mg/20 mg; 320 mg/40 mg).
Latvian: Tās ir pieejamas tabletēs (160 mg/20 mg; 320 mg/40 mg).
English: Eurartesim is taken once a day for three consecutive days, at the same time each day.
Latvian: Eurartesim tiek ieņemtas vienreiz dienā trīs dienas pēc kārtas, katru dienu vienā un tajā pašā laikā.
English: It can be used in adults and children aged 6 months and over and weighing 5 kg or more.
Latvian: Tās var lietot pieaugušajiem un bērniem no sešu mēnešu vecuma, kuri sver 5 kg vai vairāk.
English: The tablets may be crushed and mixed with water if needed.
Latvian: Nepieciešamības gadījumā var tabletes sasmalcināt un sajaukt ar ūdeni.
English: ‘Uncomplicated' means the disease does not involve severe, life-threatening symptoms.
Latvian: “Nekomplicēta” nozīmē, ka slimībai nav smagu, dzīvībai bīstamu simptomu.
English: The full EPAR for Eurartesim can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Latvian: Pilns Eurartesim EPAR teksts ir atrodams aģentūras tīmekļa vietnē: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The dose is determined by the patient's body weight.
Latvian: Deva ir atkarīga no pacienta ķermeņa svara.
English: This is a summary of the European public assessment report (EPAR) for Eurartesim.
Latvian: Šis ir Eiropas Publiskā novērtējuma ziņojuma (EPAR) kopsavilkums par Eurartesim.
English: The company will also complete a study on Eurartesim's effects on the heart.
Latvian: Uzņēmums arī pabeigs pētījumu par Eurartesim iedarbību uz sirdi.
English: Other information about Eurartesim
Latvian: Cita informācija par Eurartesim
English: It is thought to work by blocking a step in the parasite's metabolism needed for its survival.
Latvian: Uzskata, ka tas darbojas, bloķējot kādu parazīta metabolisma posmu, kas nepieciešams tā izdzīvošanai.
English: It is chemically related to other widely available medicines used to treat malaria.
Latvian: Tas ir ķīmiski līdzīgs citām plaši pieejamām zālēm, ko izmanto malārijas ārstēšanai.
English: Although the exact way in which it kills the parasite is not fully understood, it is believed to damage the parasite membrane.
Latvian: Lai gan precīzs veids, kādā tas nogalina parazītu, nav pilnībā zināms, uzskata, ka tas bojā parazīta šūnu membrānu.
English: The Eurartesim carton is to include instructions to take the medicine at least 3 hours before or after food.
Latvian: Eurartesim iepakojumā jābūt instrukcijai ieņemt zāles vismaz 3 stundas pirms vai pēc ēšanas.
English: The tablets are swallowed with water when the stomach is empty, at least three hours before or after a meal.
Latvian: Tabletes jānorij ar ūdeni tukšā dūšā vismaz trīs stundas pirms vai pēc ēšanas.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Eurartesim on 27 October 2011.
Latvian: Eiropas Komisija 2011. gada 27. oktobrī izsniedza Eurartesim reģistrācijas apliecību, kas derīga visā Eiropas Savienībā.
English: The company that markets Eurartesim will provide all doctors expected to prescribe or use Eurartesim with an educational pack containing important information on the correct use of the medicine, including a checklist of the medicines that Eurartesim must not be given with, to reduce the risk of QTc interval prolongation.
Latvian: Uzņēmums, kas tirgo Eurartesim, izsniegs visiem ārstiem, kuri varētu parakstīt vai lietot Eurartesim, izglītojošu paketi, kurā iekļauta nozīmīga informācija par zāļu pareizu lietošanu, tostarp, to zāļu kontrolsaraksts, ko nedrīkst dot vienlaicīgi, lai samazinātu QTc intervāla pagarinājuma risku.
English: The CHMP noted the potential risk for QTc interval prolongation, and included restrictions in the product information to minimise the risk to patients.
Latvian: CHMP ņēma vērā iespējamo QTc intervāla pagarinājuma risku un iekļāva zāļu aprakstā ierobežojumus, lai mazinātu risku pacientiem.
English: In adults, the most common side effects with Eurartesim (seen in between 1 and 10 patients in 100) are anaemia (low red blood cell counts), headache, QTc interval prolongation (an alteration of the electrical activity of the heart, which can cause a life-threatening abnormality of heart rhythm), tachycardia (rapid heartbeat), weakness, and fever.
Latvian: Pieaugušajiem visbiežāk novērotās Eurartesim blakusparādības (1 līdz 10 pacientiem no 100) ir anēmija (mazs sarkano asins šūnu skaits), galvassāpes, QTc pagarinājums (sirds elektriskās aktivitātes pārmaiņas, kas var izraisīt dzīvībai bīstamus sirdsdarbības ritma traucējumus), tahikardija (paātrināta sirdsdarbība), vājums un drudzis.
English: For more information about treatment with Eurartesim, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Latvian: Plašāka informācija par ārstēšanu ar Eurartesim ir pieejama zāļu lietošanas instrukcijā (kas arī ir EPAR daļa) vai sazinoties ar ārstu vai farmaceitu.
English: The Committee noted that Eurartesim meets World Health Organization recommendations for P. falciparum malaria treatment by offering a new alternative artemisinin combination therapy containing two active substances which work in different ways.
Latvian: Komiteja atzīmēja, ka Eurartesim atbilst Pasaules Veselības organizācijas ieteikumiem par P. falciparum izraisītas malārijas ārstēšanu, piedāvājot jaunu alternatīvu artemizinīna kombinētu terapiju ar divām aktīvām vielām, kas darbojas atšķirīgos veidos.
English: What measures are being taken to ensure the safe use of Eurartesim?
Latvian: Kas tiek darīts, lai nodrošinātu nekaitīgu Eurartesim lietošanu?
English: It must not be used in patients who have or are at risk of QTc interval prolongation or cardiac arrhythmias (unstable heart rhythm) or who are taking medicines that can affect heart rhythm.
Latvian: Tās nedrīkst lietot pacienti ar QTc intervāla pagarinājumu vai šāda pagarinājuma risku vai sirds aritmiju (nestabilu sirds ritmu), vai arī pacienti, kuri lieto zāles, kas var ietekmēt sirds ritmu.
English: Eurartesim must not be used in patients with severe malaria.
Latvian: Eurartesim nedrīkst nozīmēt pacientiem ar smagu malāriju.
English: In children, the most common side effects with Eurartesim (seen in more than 1 patient in 10) were influenza (flu), cough and fever.
Latvian: Bērniem visbiežāk novērotās Eurartesim blakusparādības (vairāk nekā 1 pacientam no 10) bija gripa, klepus un drudzis.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Eurartesim.
Latvian: Tajā ir paskaidrots, kā Cilvēkiem paredzēto zāļu komiteja (CHMP) novērtēja šīs zāles, pirms sniegt pozitīvu atzinumu par reģistrācijas apliecības piešķiršanu un ieteikumus par Eurartesim lietošanu.
English: In the first study, 63 days after treatment 97% of patients who received Eurartesim had been cured, compared with 95% of patients treated with the comparator medicine.
Latvian: Pirmajā pētījumā 63 dienas pēc ārstēšanas 97 % pacientu, kuri saņēma Eurartesim, bija izārstēti, salīdzinot ar 95 % pacientu, kurus ārstēja ar salīdzinājuma zālēm.
English: Therefore, the Committee concluded that the benefits of Eurartesim outweigh its risks and recommended that it be granted marketing authorisation.
Latvian: Tādēļ Komiteja nolēma, ka pacientu ieguvums, lietojot Eurartesim, pārsniedz šo zāļu radīto risku, un ieteica izsniegt šo zāļu reģistrācijas apliecību.
English: In the second study, 28 days after treatment 93% of patients who received Eurartesim had been cured, compared with 95% of patients treated with the comparator medicine.
Latvian: Otrā pētījumā 28 dienas pēc ārstēšanas 93 % pacientu, kuri saņēma Eurartesim, bija izārstēti, salīdzinot ar 95 % pacientu, kurus ārstēja ar salīdzinājuma zālēm.
English: Eurartesim is a malaria medicine that contains the active substances piperaquine tetraphosphate and artenimol.
Latvian: Eurartesim ir zāles, kas satur aktīvās vielas piperahīna tetrafosfātu un artenimolu.
English: Eurartesim was investigated in two main studies in patients with uncomplicated P. falciparum malaria.
Latvian: Eurartesim tika pētītas divos pamatpētījumos pacientiem ar nekomplicētu P. falciparum malāriju.
English: Piperaquine tetraphosphate is a so-called bisquinolone.
Latvian: Piperahīna tetrafosfāts ir tā dēvētais bis-hinolons.
English: What benefit has Eurartesim shown during the studies?
Latvian: Kādas bija Eurartesim priekšrocības šajos pētījumos?
English: Eurartesim piperaquine tetraphosphate / artenimol
Latvian: Eurartesim piperahīna tetrafosfāts/artenimols
English: Artenimol is a derivative of the naturally occurring substance artemisinin.
Latvian: Artenimols ir dabīgi sastopamas vielas artemizinīna atvasinājums.
English: The active substances in Eurartesim, piperaquine tetraphosphate and artenimol, are antimalarial substances which kill the P. falciparum parasite.
Latvian: Eurartesim aktīvās vielas piperahīna tetrafosfāts un artenimols ir pretmalārijas vielas, kas nogalina P. falciparum parazītu.
English: Malaria is an infection caused by a parasite known as Plasmodium and spread through the bite of an infected mosquito.
Latvian: Malārija ir plazmodiju parazīta izraisīta infekcijas slimība, un tā izplatās ar inficēta knišļa kodumu.
English: Why has Eurartesim been approved?
Latvian: Kāpēc Eurartesim tika apstiprinātas?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Eurartesim have also been included in the summary of product characteristics and the package leaflet.
Latvian: Zāļu aprakstā un lietošanas instrukcijā ir iekļauti arī ieteikumi un piesardzības pasākumi, kas jāievēro veselības aprūpes speciālistiem un pacientiem nekaitīgas un efektīvas Eurartesim lietošanas nolūkos.
English: The main measure of effectiveness was the proportion of patients who were cured 63 days after treatment.
Latvian: Galvenais iedarbīguma rādītājs bija to pacientu skaits, kurus izārstēja pēc 63 terapijas dienām.
English: The CHMP considered that Eurartesim had been shown to be effective in treating uncomplicated P. falciparum malaria while the side effects were similar to those seen with comparable treatments.
Latvian: CHMP uzskatīja, ka ir pierādīta Eurartesim efektivitāte nekomplicētas P. falciparum malārijas ārstēšanā, bet blakusparādības ir līdzīgas kā citiem līdzīgiem terapijas līdzekļiem.
English: The main measure of effectiveness was the proportion of patients who were cured 28 days after treatment.
Latvian: Galvenais iedarbīguma rādītājs bija to pacientu skaits, kuri bija izārstēti pēc 28 terapijas dienām.
English: In the second study, Eurartesim was compared with another medicine containing artemether and lumefantrine in 1,553 children.
Latvian: Otrā pētījumā ar 1553 bērniem Eurartesim tika salīdzinātas ar citām zālēm, kas satur artemeteru un lumefantrīnu.
English: In the first study, Eurartesim was compared with another malaria medicine containing artesunate and mefloquine in 1,150 patients.
Latvian: Pirmajā pētījumā ar 1150 pacientiem Eurartesim tika salīdzinātas ar citām pretmalārijas zālēm, kas satur artesunātu un meflohīnu.
English: What is Eurartesim?
Latvian: Kas ir Eurartesim?
English: For the full list of all side effects with Eurartesim, see the package leaflet.
Latvian: Pilns visu Eurartesim izraisīto blakusparādību saraksts ir atrodams zāļu lietošanas instrukcijā.
English: Eurartesim was shown to be effective in treating uncomplicated P. falciparum malaria.
Latvian: Tika pierādīts, ka Eurartesim efektīvi ārstē nekomplicētu P. falciparum malāriju.
English: What is the risk associated with Eurartesim?
Latvian: Kāds risks pastāv, lietojot Eurartesim?
English: Eurartesim is used to treat uncomplicated malaria caused by the Plasmodium falciparum parasite.
Latvian: Eurartesim lieto Plasmodium falciparum parazīta izraisītas nekomplicētas malārijas ārstēšanai.
English: How does Eurartesim work?
Latvian: Kā Eurartesim darbojas?
English: How has Eurartesim been studied?
Latvian: Kā noritēja Eurartesim izpēte?
English: How is Eurartesim used?
Latvian: Kā lieto Eurartesim?
English: What is Eurartesim used for?
Latvian: Kāpēc lieto Eurartesim?
English: Its exact mechanism of action is unknown, but it attaches to several different receptors on nerve cells in the brain.
Latvian: Tā darbības mehānisms nav precīzi zināms, bet ir noskaidrots, ka tas piesaistās vairākiem atšķirīgiem receptoriem uz smadzeņu nervu šūnām.
English: Therefore, the CHMP's view was that, as for Abilify, the benefit outweighs the identified risk.
Latvian: Tāpēc CHMP uzskatīja, ka ieguvumi tāpat kā Abilify gadījumā pārsniedz identificēto risku.
English: The full EPAR and risk management plan summary for Aripiprazole Sandoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Latvian: Pilns Aripiprazole Sandoz EPAR teksts un riska pārvaldības plāna kopsavilkums ir atrodams aģentūras tīmekļa vietnē: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This means that it is similar to a ‘reference medicine', but it contains aripiprazole at a new strength in addition to existing strengths: while the reference medicine, Abilify, is available as 5, 10, 15 and 30 mg, Aripiprazole Sandoz is also available as 20 mg tablets.
Latvian: Tas nozīmē, ka tās ir līdzīgas “atsauces zālēm”, bet papildus esošajiem stiprumiem satur jaunu aripiprazola stiprumu - atsauces zāles Abilify ir pieejamas 5, 10, 15 un 30 mg devās, Aripiprazole Sandoz ir pieejamas arī kā 20 mg tabletes.
English: This is a summary of the European public assessment report (EPAR) for Aripiprazole Sandoz.
Latvian: Šis ir Eiropas Publiskā novērtējuma ziņojuma (EPAR) kopsavilkums par Aripiprazole Sandoz.
English: In this way, aripiprazole helps to change the activity of the nerve cells which are thought to give rise to psychotic or manic symptoms and preventing them from returning.
Latvian: Šādā veidā aripiprazols maina to nervu šūnu aktivitāti, ko uzskata par psihotisko vai mānijas simptomu cēloni, kā arī novērš to aktivitātes atjaunošanos.
English: What measures are being taken to ensure the safe and effective use of Aripiprazole Sandoz?
Latvian: Kas tiek darīts, lai nodrošinātu nekaitīgu un efektīvu Aripiprazole Sandoz lietošanu?
English: It is not intended to provide practical advice on how to use Aripiprazole Sandoz.
Latvian: Tas nav paredzēts kā praktiski ieteikumi par Aripiprazole Sandoz lietošanu.
English: Aripiprazole Sandoz is available as tablets and can only be obtained with a prescription.
Latvian: Aripiprazole Sandoz ir pieejamas tabletēs, un tās var iegādāties tikai pret recepti.
English: In addition, when used for patients aged 13 years or older with moderate to severe manic episodes in bipolar I disorder, the company that markets Aripiprazole Sandoz will provide educational materials to be supplied to patients or their caregivers and to doctors to explain the safe use of the medicine in these patients.
Latvian: Turklāt, lietojot pacientiem, kuri ir 13 gadus veci vai vecāki ar I tipa bipolāriem traucējumiem un vidējām vai smagi izteiktām mānijas epizodēm, uzņēmums, kas laiž apgrozībā Aripiprazole Sandoz, pacientiem vai to aprūpētājiem, kā ari ārstiem nodrošinās izglītojošus materiālus, kuros izskaidros, kā šīs zāles lietot droši.
English: This means that aripiprazole acts like dopamine and 5-hydroxytryptamine by activating these receptors, but less strongly than the neurotransmitters.
Latvian: Tas nozīmē, ka, aktivizējot šos receptorus, aripiprazols darbojas tāpat kā dopamīns un 5-hidroksitriptamīns, bet ne tik spēcīgi kā neirotransmiteri.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Aripiprazole Sandoz has been shown to have comparable quality and to be bioequivalent to Abilify.
Latvian: Aģentūras Cilvēkiem paredzēto zāļu komiteja (CHMP) secināja, ka saskaņā ar ES prasībām Aripiprazole Sandoz un Abilify ir pierādīta kvalitātes līdzvērtība un bioekvivalence.
English: The Committee recommended that Aripiprazole Sandoz be approved for use in the EU.
Latvian: Komiteja ieteica apstiprināt Aripiprazole Sandoz lietošanai ES.
English: The dose should be adjusted in patients who are taking other medicines that affect the way Aripiprazole Sandoz is broken down in the body.
Latvian: Pacientiem, kuri lieto citas zāles, kas ietekmē Aripiprazole Sandoz noārdīšanos organismā, deva ir jāpielāgo.
English: Aripiprazole Sandoz is used in adults to treat moderate to severe manic episodes and to prevent new manic episodes in adults whose illness has improved with the medicine in the past.
Latvian: Aripiprazole Sandoz lieto pieaugušajiem, lai ārstētu mērenas līdz smagas mānijas epizodes un lai novērstu jaunas mānijas epizodes pieaugušajiem, kuriem iepriekš, lietojot šīs zāles, stāvoklis ir uzlabojies.
English: Because Aripiprazole Sandoz is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Latvian: Tā kā Aripiprazole Sandoz ir bioekvivalentas atsauces zālēm, to ieguvumu un riska attiecību uzskata par līdzvērtīgu atsauces zāļu ieguvumu un riska attiecībai.
English: A risk management plan has been developed to ensure that Aripiprazole Sandoz is used as safely as possible.
Latvian: Lai nodrošinātu iespējami nekaitīgu Aripiprazole Sandoz lietošanu, ir izstrādāts riska pārvaldības plāns.
English: The company carried out ‘bioequivalence' studies to show that Aripiprazole Sandoz is bioequivalent to the reference medicine, Abilify.
Latvian: Uzņēmums veica “bioekvivalences” pētījumus, lai pierādītu Aripiprazole Sandoz bioekvivalenci atsauces zālēm Abilify.
English: For practical information about using Aripiprazole Sandoz, patients should read the package leaflet or contact their doctor or pharmacist.
Latvian: Lai iegūtu praktisku informāciju par Aripiprazole Sandoz lietošanu, pacientiem jāizlasa zāļu lietošanas instrukcija vai jāsazinās ar ārstu vai farmaceitu.
English: Other information about Aripiprazole Sandoz
Latvian: Cita informācija par Aripiprazole Sandoz
English: Aripiprazole Sandoz is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over.
Latvian: Aripiprazole Sandoz arī lieto līdz 12 nedēļām ilgi vidēji līdz smagi izteiktu mānijas epizožu ārstēšanai pacientiem no 13 gadu vecuma.